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Abstract
Background
Human monkeypox (MPX) occurs at appreciable rates in the Democratic Republic of Congo
(DRC). Infection with varicella zoster virus (VZV) has a similar presentation to that of MPX,
and in areas where MPX is endemic these two illnesses are commonly mistaken. This study
evaluated the diagnostic utility of two surveillance case definitions for MPX and specific clini-
cal characteristics associated with laboratory-confirmed MPX cases.
Methodology/Principal findings
Data from a cohort of suspect MPX cases (identified by surveillance over the course of a 42
month period during 2009–2014) from DRC were used; real-time PCR diagnostic test
results were used to establish MPX and VZV diagnoses. A total of 333 laboratory-confirmed
MPX cases, 383 laboratory-confirmed VZV cases, and 36 cases that were determined to
not be either MPX or VZV were included in the analyses. Significant (p<0.05) differences
between laboratory-confirmed MPX and VZV cases were noted for several signs/symptoms
including key rash characteristics. Both surveillance case definitions had high sensitivity
and low specificities for individuals that had suspected MPX virus infections. Using 12 signs/
symptoms with high sensitivity and/or specificity values, a receiver operator characteristic
analysis showed that models for MPX cases that had the presence of ‘fever before rash’
plus at least 7 or 8 of the 12 signs/symptoms demonstrated a more balanced performance
between sensitivity and specificity.
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Conclusions
Laboratory-confirmed MPX and VZV cases presented with many of the same signs and
symptoms, and the analysis here emphasized the utility of including 12 specific signs/symp-
toms when investigating MPX cases. In order to document and detect endemic human MPX
cases, a surveillance case definition with more specificity is needed for accurate case detec-
tion. In the absence of a more specific case definition, continued emphasis on confirmatory
laboratory-based diagnostics is warranted.
Author summary
Human monkeypox is the most significant Orthopoxvirus infection since the eradication
of smallpox. The disease is endemic in Africa and the majority of cases occur in the
Congo Basin. Correct identification of patients is critical to deployment of efficient con-
trol measures to prevent further transmission and appropriate care for the patient. An
evaluation of two surveillance case definitions revealed that the definitions had high sensi-
tivities but low specificities for correct case identification, which results in the identifica-
tion of patients with other rash illnesses. Several signs and symptoms of laboratory-
confirmed monkeypox cases were identified that could be used to aid in the development
of surveillance case definitions to correctly identify cases. Laboratory diagnostics continue
to be an important part of correct patient identification in order to control the disease and
provide adequate care.
Introduction
Since the global eradication of smallpox, the most important Orthopoxvirus infection in
humans in terms of ongoing numbers of cases, morbidity, and mortality has been human
monkeypox (MPX) [1, 2]. Monkeypox virus (MPXV) is maintained by an enzootic cycle, with
zoonotic introductions to humans often being followed by more limited human-to-human
transmission [3, 4]. The animal reservoir for MPXV remains unknown, but the virus has been
isolated in the wild from a squirrel (Funisciurus anerythrus) and a sooty mangabey (Cercocebus
atys) [5, 6].
Infection with MPXV can lead to a smallpox-like illness characterized by a febrile pro-
drome, lasting 1–4 days, followed by a slowly progressing rash. The rash proceeds from mac-
ules to papules to vesicles to pustules to crusts and finally to desquamation. This occurs over a
period of two to four weeks. At any given site on the body, the rash is generally in the same
stage of development (e.g., all vesicles), and the lesions are typically circumscribed, umbili-
cated, deep-seated and firm. The rash has a centrifugal distribution, with a concentration of
lesions on the extremities and face. As with smallpox, MPX lesions often appear on the palms
of the hands and soles of the feet. Lymphadenopathy (inguinal, axillary, and/or cervical) is
common in MPX patients and can occur prior to or at the onset of rash. Ocular infection with
MPXV can lead to permanent corneal scarring and blindness [7–9].
Infection with varicella zoster virus (VZV) has a similar presentation to that of MPXV
infection, and in areas where MPXV is endemic these two illnesses are commonly mistaken
[10, 11]. However, there are several features of illness that typically set one infection apart
from the other. For example, VZV patients typically exhibit a short, mild period of febrile
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prodrome, or none at all, followed by a quickly evolving (1–2 day) pleomorphic rash (i.e., a
rash for which neighboring lesions may be in different stages of development). VZV lesions
also often have irregular borders, and are superficial on the surface of the skin (relative to
those of MPX). In addition, varicella lesions often appear in a centripetal distribution on the
body [9, 12]. Although noted in rare occurrences, lesions on the palms of the hands and soles
of the feet are not hallmarks of VZV infections [13]. VZV patients do not typically have pro-
nounced lymphadenopathy, and, thus, the presence of lymphadenopathy is one distinguishing
characteristic that can differentiate MPX from both smallpox and varicella. Additional illnesses
that can be mistaken for MPX are other herpetic infections (in addition to VZV), drug erup-
tions, syphilis, yaws, scabies, and rickettsialpox [9]. Specimen collection followed by laboratory
testing can be difficult to accomplish for all suspected cases in MPX endemic areas. A clinical
case definition capable of enhancing the distinction between MPX and other illnesses would
be useful to enable more accurate and expedient case detection, collection of higher-quality
surveillance data, and improved patient management.
MPXV is enzootic in western and central Africa, with the overwhelming majority of human
infections reported each year from the forested areas of the Congo Basin of Democratic
Republic of Congo (DRC) [2]. MPX is a nationally reportable disease in DRC and has been
identified as one of the country’s priority diseases of epidemic potential. On a bi-weekly basis,
notifications of suspected MPX cases from each of the country’s Health Zones are submitted
to national public health authorities; few of the suspected cases are formally investigated (i.e.,
case investigation forms completed and diagnostic specimens collected).
This study evaluates the diagnostic utility of two surveillance case definitions for MPX.
Both definitions were herein applied to a cohort of suspected MPX cases that were identified
over the course of a 42 month period via surveillance in one Province in DRC. This cohort is
unique in that the dataset contained an in-depth list of signs/symptoms. The accuracy of case
classification was determined using laboratory findings. We assessed clinical features of illness
in patients with confirmed MPXV infection to identify characteristics distinctly associated
with disease presentation and suggest modifications to the MPX surveillance case definition to
improve specificity.
Methods
Suspect case detection and laboratory classification
Data from suspect MPX cases were obtained by investigation in accordance with national
guidelines. Patients were identified as suspect MPX cases if they had a vesicular or pustular
eruption with deep-seated, firm pustules and at least one of the following symptoms: fever pre-
ceding the eruption, lymphadenopathy (inguinal, axillary, or cervical), and/or pustules or
crusts on the palms of the hands or soles of the feet. For suspect cases, a MPX-specific case
investigation form was completed and, in most instances, two or more diagnostic specimens
were collected from each suspected MPX case. The specimens were sent to the Institut
National de Recherche Biome´dicale (INRB) in Kinshasa for diagnostic testing. One specimen
from each individual was tested at INRB for the presence of Orthopoxvirus DNA signatures
using a real-time PCR assay [14]. If the initial PCR was negative for Orthopoxvirus, a second
real-time PCR assay specific for VZV-specific DNA signatures was conducted (reagents pro-
vided by the United States Army Medical Research Institute of Infectious Diseases). DNA
extracted at INRB and additional independent specimens, if available, were shipped to the
Poxvirus Laboratory at the U.S. Centers for Disease Control and Prevention (CDC). At the
CDC, DNA was extracted from original specimens and all specimens were tested with MPXV
and VZV-specific real-time PCR assays [15, 16].
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An individual was classified as a laboratory-confirmed MPX case if at least one specimen
was 1) positive with the Orthopoxvirus-specific assay, and/or 2) positive by MPX-specific real-
time PCR. An individual was independently classified as a laboratory-confirmed VZV case if a
crust specimen tested positive for VZV DNA signatures at INRB or if an original vesicular
swab or crust specimen tested positive for VZV at CDC.
Ethical statement
These activities were determined to not be research by a CDC human subjects advisor.
Dataset and variable inclusion for analyses
Suspect MPX cases in Tshuapa Province, DRC, with rash onset occurring between September
2009 and February 2014 were included in the analysis (N = 1025, Fig 1). These individuals
were all assessed by a surveillance officer, who determined the individual met the surveillance
case definition for a suspect MPX case. Individuals whose laboratory test results were sugges-
tive of a coinfection with both MPXV and VZV, and those with incomplete or inconsistent
laboratory results were excluded from analyses (n = 273). A total of 752 cases were included
for further analyses; 333 laboratory-confirmed MPX cases, 383 laboratory-confirmed VZV
cases, and 36 cases that were determined to not be either MPX or VZV (laboratory diagnosis
undetermined).
Clinical signs and symptoms were recorded as checkboxes—‘yes’, ‘no’, and ‘do not know’—
on the case investigation form. If an individual case investigation form had a response (‘yes or
‘no’) for any signs/symptoms, but the absence of a response for another specific sign/symptom
the variable was coded as “missing” for the specific sign/symptom without a response. Febrile
prodrome status was determined by either a) selection of ‘yes/no’ for the febrile prodrome var-
iable on the case investigation form, or, if that information was missing, by, b) presence of pro-
drome was ascertained by determining the time interval between onset of fever and that of
rash, when the information was available. The presence of lymphadenopathy was determined
using the individual lymphadenopathy-type fields (inguinal, axillary, cervical). If at least one
category of lymphadenopathy was reported as present, then the individual was coded “yes” for
lymphadenopathy; if all fields were “no”, the individual was coded “no” for lymphadenopathy.
If one or more of the fields were missing and others were “no”, the individual was coded “miss-
ing” for lymphadenopathy.
Two surveillance case definitions were evaluated in this study. According to Case Definition
A, a suspect case is an individual with fever followed by a vesicular or pustular rash with the
following symptoms: rash on palms, soles, and face; or the presence of 5 variola-like scars.
Case Definition A has been recommended for use in endemic areas.
Case Definition B was developed as a discriminatory case definition with the inclusion of
several criteria that distinguish MPX from VZV. Case Definition B encompasses individuals
who have a vesicular or pustular eruption with deep-seated, firm pustules and at least one of
the following symptoms: fever preceding the eruption, lymphadenopathy (inguinal, axillary, or
cervical), and/or pustules or crusts on the palms of the hands or soles of the feet.
To evaluate the diagnostic accuracy of each case definition, the dataset was restricted to
individuals who had all the information needed for classification using both case definitions
(i.e., one dataset was used for the independent analyses of both definitions). A total of 645 of
the 752 cases (85.8%) had sufficient information to be included in the analyses of both case def-
initions; 314 laboratory-confirmed MPX cases, 305 laboratory-confirmed VZV cases, and 26
cases that were determined to be neither MPX nor VZV (Fig 1). Individuals met the criteria
for Case Definition A if they had a febrile prodrome and either the presence of a) rash/scars on
Surveillance case definitions for human monkeypox
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Fig 1. Flow chart of the cases selected for each analysis.
https://doi.org/10.1371/journal.pntd.0005857.g001
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the face, palms, and soles, or b) more than 5 scars. Individuals met the criteria for Case Defini-
tion B if they had rash with deep-seated, firm lesions and either a) febrile prodrome, b) lymph-
adenopathy, or c) lesions on the palms of the hands or soles of the feet. This dataset was also
used for the receiver operating characteristic analysis.
Statistical analysis
The frequencies of each sign/symptom were calculated for all cases included in the dataset,
and individually for laboratory-confirmed MPX and VZV cases. Associations between
reported signs/symptoms and laboratory determined diagnoses were calculated using chi-
squared and Fisher exact tests. Signs/symptoms that occurred with significantly different fre-
quency (p<0.05) between laboratory-confirmed MPX and VZV cases were further assessed
for their individual sensitivity, specificity, PPV and NPV in relation to the confirmed diagnosis
of MPX.
For the analysis of the two case definitions, real-time PCR diagnostic test results (for MPX
and VZV) were used as the ‘gold standard’ to establish MPX and VZV diagnoses. The sensitiv-
ity, specificity, positive predictive values (PPV), and negative predictive values (NPV) were
computed for the two case definitions.
A receiver operating characteristic (ROC) analysis was completed using ‘fever before rash’
and various summed frequencies of the 12 signs/symptoms that were identified as having high
(>80%) sensitivities or specificities for laboratory-confirmed MPX cases. For example, indi-
viduals with ‘fever plus rash’ and one of these 12 signs/symptoms were categorized as having ‘1
criteria’; individuals with ‘fever plus rash’ and 12 signs/symptoms were ranked as ‘12 criteria’.
Each of these 12 signs/symptoms counted equally to the sum. For example, if an individual
reported two symptoms of ‘nausea’ and ‘cough’, they were categorized the same as an individ-
ual who reported two symptoms of ‘fatigue’ and ‘conjunctivitis’. ‘Fever before rash’ was identi-
fied as a mandatory sign/symptom because this has been consistently noted in the literature
for MPX patients and also was observed at a frequency of 98.1% for all suspect cases and 99.1%
for laboratory-confirmed MPX patients in the present analysis. The sensitivity, specificity,
PPV and NPV for each model (with increasing number of signs and symptoms from 1 to 12)
were assessed.
All data analysis was performed using SAS version 9.3.
Results
Characteristics of the Population: A total of 752 suspect cases were included in the analysis.
Approximately 53% of suspect cases were male and 46% were female; this proportion
remained consistent after laboratory case classification. The mean age of suspect cases was 17
years (median 13, range 0.01–86). Of these suspect cases, 333 (44.3%) individuals were classi-
fied as laboratory-confirmed MPX cases and 419 (55.7%) were classified as laboratory-con-
firmed VZV (383) or undiagnosed (36) cases (Table 1).
Performance of specific clinical characteristics: With the objective of improving the speci-
ficity and PPV of the case definitions under examination, associations between the reported
clinical signs/symptoms and a laboratory-confirmed diagnosis of MPX (versus VZV) were
investigated. Significant (p<0.05) differences between laboratory-confirmed MPX and VZV
cases were noted for the signs/symptoms of nausea, cough, lymphadenopathy (overall and
each site), mouth ulcers, sore throat, malaise, fatigue, conjunctivitis, sensitivity to light, and
bedridden (Table 2). Rash characteristics that were significantly different included same size,
deep-seated, firm lesions, and the presence of lesions on the arms, legs, palms of the hands,
soles of the feet, and genitals. Each of the significant signs/symptoms and rash characteristics
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occurred more frequently in laboratory-confirmed MPX cases than in laboratory-confirmed
VZV cases. The majority of significant signs/symptoms (15/20) occurred in more than 50% in
laboratory-confirmed MPX cases.
Variables with high sensitivity for MPX (80%) were lymphadenopathy, fatigue, and the
following rash characteristics: same size, deep-seated firm lesions, presence on the arms, legs,
palms of the hands, and soles of the feet (Table 3). Nausea, conjunctivitis, bedridden, and
lesions present on the genitals were signs/symptoms with a high specificity (80%), but none
of these, individually, were found in laboratory-confirmed MPX cases at a frequency > 32%.
Analysis of the case definitions: Two-by-two tables and diagnostic values for the two case
definitions are presented in Tables 4 and 5. Two hundred ninety-one (92.6%) laboratory-con-
firmed MPX cases satisfied Case Definition A; and 306 (97.5%) laboratory-confirmed MPX
cases satisfied Case Definition B; 245 (74%) and 303 (91.5%) non-MPX cases [laboratory-con-
firmed VZV cases and undiagnosed (MPX and VZV negative) cases] satisfied Case Definitions
A and B, respectively.
The sensitivity of both case definitions was high, with the value for the Case Definition B a
bit higher than that of Case Definition A (97.45% vs. 92.86%, respectively). Similarly, the speci-
ficity of both case definitions was low and the Case Definition A had a higher specificity
(25.98%) than Case Definition B (8.46%). The PPVs were similar for both definitions (50.25%
for Case Definition B and 54.92% for Case Definition A), as were the NPVs (77.78% for Case
Definition B and 78.90% for Case Definition A). The NPV was higher than the PPV for both
definitions.
Receiver operating characteristic analysis: Using the 12 identified signs/symptoms with
high sensitivity and/or specificity values, the ROC analysis tested the performance and accu-
racy of 12 models (with increasing numbers of signs and symptoms) (Table 6). In general,
models with a greater number of signs/symptoms (>8 but<12) demonstrated excellent speci-
ficity (>90%) but low sensitivity (<40%). In contrast, models with a lower number of signs/
symptoms (<7) had excellent sensitivity (>90%) but low specificity (<40%). The models for
MPX cases that had the presence of ‘fever before rash’ plus at least 7 or 8 of the 12 signs/symp-
toms demonstrated a more balanced performance between sensitivity and specificity. There
was greatly improved specificity for the models that included 7 (50.76%) or 8 (70.69%) signs/
symptoms when compared to either Case Definition A (25.98%) or B (8.46%). The area under
the curve for the model using these summed symptom counts was 0.74 (Fig 2).
Table 1. Characteristics of suspect monkeypox (MPX) cases identified between December 2009 and February 2014 (n = 752).
Total Laboratory-confirmed MPX cases Laboratory-confirmed VZV Undiagnosed casesa
All suspect cases 752 (100%) 333 (44.3%) 383 (50.9%) 36 (4.8%)
Sexb
Male
Female
Missing
397 (52.9%)
349 (46.4%)
6 (0.8%)
178 (53.4%)
154 (46.2%)
1 (0.3%)
205 (53.5%)
174 (45.4%)
4 (1.0%)
14 (38.9%)
21 (58.3%)
1 (2.8%)
Age (years)
Mean
Median
Range
Missing
17.04
13.33
0.01–86
3
5.77
13.82
0.08–67
n/a
18.15
13
0.01–86
2
16.98
14.72
0.8–46
1
a Undiagnosed cases are those that were determined to not be either MPX or VZV.
b Percentages for sex are within column percentages
https://doi.org/10.1371/journal.pntd.0005857.t001
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Discussion
The choice and utility of a case definition will be guided by its intended use. Case Definition A
was designed to detect a single case of MPX illness, followed by an immediate outbreak
response and control efforts. Case Definition B was designed to be a discriminatory definition
used in the context of surveillance for disease, to better understand the extent and burden of
disease in an endemic area. Both case definitions were characterized by high sensitivities but
very low specificities. The high values for sensitivity were expected since the dataset repre-
sented patients who were diagnosed with suspected MPX virus infection (prior to laboratory
confirmation). These characteristics indicate that both definitions are useful for screening pur-
poses and are well-designed for outbreak detection. Given that MPX is an endemic, regularly
Table 2. Association between clinical characteristics and laboratory-confirmed monkeypox (MPX) or varicella (VZV) case classification.
Sign or Symptom All suspect cases (752) Laboratory-confirmed MPX
cases (333)
Laboratory-confirmed VZV
cases (383)
p-valuea
nb Nb % n N % n N %
Fever 732 737 99.3% 329 329 100% 371 376 98.7% 0.0644
Rash 718 750 95.7% 316 332 95.2% 367 382 96.1% 0.5594
Febrile Prodrome 727 741 98.1% 327 330 99.1% 371 379 97.9% 0.1965
Nausea 140 737 19.0% 75 328 22.9% 58 374 15.5% 0.0131
Cough 347 744 46.6% 192 331 58.0% 135 378 35.7% <0.0001
Lymphadenopathy 562 731 76.9% 277 325 85.2% 265 371 71.4% <0.0001
Axillary 369 737 50.1% 191 327 58.4% 166 375 44.3% 0.0002
Cervical 416 736 56.5% 206 326 63.2% 195 375 52.0% 0.0028
Inguinal 323 738 43.8% 168 326 51.5% 142 377 37.7% 0.0002
Chills 593 744 79.7% 262 328 79.9% 302 381 79.3% 0.8400
Mouth ulcers 333 741 44.9% 190 326 58.3% 131 381 34.4% <0.0001
Sore Throat 451 738 61.1% 246 325 75.7% 188 378 49.7% <0.0001
Headache 548 729 75.2% 243 322 75.5% 283 373 75.9% 0.9011
Pruritis 379 734 51.6% 170 321 53.0% 196 378 51.9% 0.7701
Malaise 453 720 62.9% 228 319 71.5% 211 367 57.5% 0.0001
Fatigue 590 740 79.7% 278 328 84.8% 286 377 75.9% 0.0032
Conjunctivitis 126 739 17.1% 79 328 24.1% 43 377 11.4% <0.0001
Sensitivity to light 198 729 27.2% 105 323 32.5% 86 372 23.1% 0.0057
Bedridden 137 743 18.4% 95 327 29.1% 41 381 10.8% <0.0001
Rash characteristics
Monomorphic 573 658 87.1% 286 319 89.7% 264 312 84.6% 0.0585
Same size 581 657 88.4% 291 319 91.2% 264 311 84.9% 0.0063
Deep-seated and firm 621 660 94.1% 310 319 97.2% 286 314 91.1% 0.0011
Rash site
Face 736 743 99.1% 330 333 99.1% 372 375 99.2% 0.8838
Thorax 723 743 97.3% 328 333 98.5% 362 375 96.5% 0.0973
Arms 704 742 94.9% 326 332 98.2% 345 375 92.0% 0.0002
Legs 331 352 94.0% 191 197 97.0% 125 138 90.6% 0.013
Palms 677 742 91.2% 324 333 97.3% 319 374 85.3% <0.0001
Soles 604 743 81.3% 309 333 92.8% 264 375 70.4% <0.0001
Genitals 144 692 20.8% 87 309 28.2% 52 349 14.9% <0.0001
a Chi-square test between laboratory-confirmed MPX and VZV cases. Significant p-values (p<0.05) are in bold.
b n is the number of cases reported to have the sign/symptom and N is the total number of cases with data present.
https://doi.org/10.1371/journal.pntd.0005857.t002
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occurring, reportable disease in Tshuapa Province, the case definitions should be sufficient to
capture true MPX cases, such that local or national officials may want to launch an outbreak
response if they observe an aberration or threshold in the number or rate of reported infec-
tions. For surveillance purposes, however, especially in resource-limited countries such as
DRC, it is necessary for a definition to capture all true cases and at the same time minimize the
number of false positives. Attributes of Case Definition B, including a low specificity and mod-
erate PPV, are not optimal for the objectives of disease surveillance. Observations of a moder-
ate PPV and high NPV for both case definitions is consistent with a disease with a low
prevalence in the population. Although prominent and regularly occurring, MPX does have a
Table 3. Diagnostic measuresa of significantb clinical signs/symptoms.
Symptom Sensitivityc Specificityc PPV NPV
Nausea 22.87% (18.32–27.41) 84.11% (80.56–87.65) 53.57% (45.31–61.83) 57.62% (53.66–61.59)
Cough 58.01% (52.69–63.32) 62.47% (57.80–67.14) 55.33% (50.1–60.56) 64.99% (60.30–69.68)
Lymphadenopathy 85.23% (81.37–89.09) 29.80% (25.35–34.25) 49.29% (45.15–53.42) 71.60% (64.80–78.40)
Axillary 58.41% (53.07–63.75) 56.59% (51.79–61.38) 51.76% (46.66–56.86) 63.04% (58.11–67.98)
Cervical 63.19% (57.95–68.43) 48.78% (43.94–53.62) 49.52% (44.71–54.32) 62.50% (57.20–67.80)
Inguinal 51.53% (46.11–56.96) 62.38% (57.70–67.06) 52.01% (46.56–57.46) 61.93% (57.26–66.60)
Mouth ulcers 58.28% (52.93–63.63) 65.54% (60.97–70.11) 57.06% (51.74–62.37) 66.67% (62.09–71.24)
Sore Throat 75.69% (71.03–80.36) 50.36% (45.54–55.19) 54.55% (49.95–59.14) 72.47% (67.31–77.64)
Malaise 71.47% (66.52–76.43) 43.89% (39.03–48.75) 50.33% (45.73–54.94) 65.92% (60.23–71.60)
Fatigue 84.76% (80.87–88.65) 24.27% (20.13–28.41) 47.12% (43.09–51.15) 66.67% (59.12–74.21)
Conjunctivitis 24.09% (19.46–28.71) 88.56% (85.49–91.64) 62.70% (54.25–71.14) 59.38% (55.49–63.27)
Sensitivity to light 32.51% (27.4–37.62) 77.09% (73.01–81.18) 53.03% (46.08–59.98) 58.95% (54.76–63.13)
Bedridden 29.05% (24.13–33.97) 89.90% (87.01–92.8) 69.34% (61.62–77.06) 61.72% (57.85–65.59)
Rash characteristics
Same size 91.85% (88.85–94.85) 14.79% (11.01–18.58) 50.43% (46.36–54.50) 65.79% (55.12–76.46)
Deep-seated and firm 97.18% (95.36–99.00) 8.80% (5.79–11.80) 49.92% (45.99–53.85) 76.92% (63.70–90.15)
Rash site
Arms 98.19% (96.76–99.63) 7.80% (5.21–10.40) 46.31% (42.62–49.99) 84.21% (72.62–95.80)
Legs 96.95% (94.55–99.35) 9.68% (5.02–14.33) 57.70% (52.38–63.03) 71.43% (52.11–90.75)
Palms 97.30% (95.56–99.04) 13.69% (10.36–17.02) 47.86% (44.10–51.62) 86.15% (77.76–94.55)
Soles 92.79% (90.02–95.57) 28.05% (23.70–32.40) 51.16% (47.17–55.15) 82.73% (76.45–89.02)
Genitals 28.16% (23.14–33.17) 84.86% (81.27–88.45) 60.00% (52.03–67.97) 59.41% (55.30–63.53)
a Each diagnostic measure is presented with the 95% confidence interval.
b Significant clinical characteristics were chosen from a comparison of laboratory-confirmed MPX and VZV cases, Table 2.
c Diagnostic measures with values80% are in bold.
https://doi.org/10.1371/journal.pntd.0005857.t003
Table 4. The number of suspect monkeypox (MPX) cases that were captured by Case Definitions A and B by their MPX laboratory case
classification.
Laboratory- confirmed MPX Case a Case Definition A Case Definition B
Captured Not captured Total Captured Not captured Total
Yes 291 23 314 306 8 314
No 245 86 331 303 28 331
Total 536 109 645 609 36 645
a MPX case classification determined by laboratory test results.
https://doi.org/10.1371/journal.pntd.0005857.t004
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relatively low incidence in Tshuapa Province with a cumulative incidence rate of 4.8/10,000
over a four year period (data available upon request).
Several signs/symptoms had a high sensitivity (lymphadenopathy, fatigue, and the following
rash characteristics: same size, deep-seated firm lesions, presence on the arms, legs, palms of
the hands, and soles of the feet), which indicates that these signs/symptoms may be useful in
ruling out other febrile rash illnesses that may be circulating in an area of active MPXV trans-
mission. Signs/symptoms with a high specificity (nausea, conjunctivitis, bedridden, lesions
present on the genitals), on the other hand, may be useful in identifying true MPX cases. These
four signs/symptoms and, also, sensitivity to light were characteristics that occurred more fre-
quently in laboratory-confirmed MPX cases than VZV cases. However, none of these discrimi-
natory signs/symptoms were found at a high frequency in MPX cases (<50%). Thus, these
signs/symptoms may be eligible components of a case definition to identify MPX cases, how-
ever, they cannot be a mandatory component.
Case definitions for MPX include characteristics of disease presentation specific to the rash
itself. This analysis reinforced the inclusion of lesion size and surface presentation (deep-
seated vs superficial). Notably, the “characteristic” lesion locations of palms of the hands and
soles of the feet, although present in higher frequency in MPX cases than VZV cases, were
prevalent in all suspect cases (91.2% and 81.3%, respectively) and were not helpful in increas-
ing the specificity for MPX cases. Lesions on the palms and soles have been previously noted
in VZV cases in central Africa [13], and the findings here indicate that this presentation may
be more common than recognized before.
The benefit of an ROC analysis is that one is able to evaluate the effect of increasing number
of signs and symptoms on the sensitivity and specificity of case identification. Both laboratory-
confirmed MPX and VZV cases presented with many of the same signs and symptoms. Instead
of limiting the case definition to an all-or-nothing analysis, we chose to limit the ROC analysis
to a subset of highly sensitive and specific signs/symptoms. As such, the analysis indicated that
the combination of 7 or 8 signs/symptoms was the most optimal model to accurately predict
laboratory-confirmed MPX cases. This analysis emphasized the utility of including the mini-
mum 12 signs/symptoms (nausea, conjunctivitis, bedridden, lesions on genitals,
Table 5. Summary of the diagnostic parameters for both case definitions.
Parameter Case Definition Aa Case Definition Ba
Sensitivity 92.68% (89.79–95.56) 97.45% (95.71–99.20)
Specificity 25.98% (21.26–30.71) 8.46% (5.46–11.46)
PPV 54.29% (50.07–58.51) 50.25% (46.28–54.22)
NPV 78.90% (71.24–86.56) 77.78% (64.20–91.36)
a % (95% confidence interval)
https://doi.org/10.1371/journal.pntd.0005857.t005
Table 6. Accuracy of the minimum number of signs/symptoms in predicting laboratory-confirmed monkeypox cases.
No. signs/ symptomsa 1 2 3 4 5 6 7 8 9 10 11 12
Sensitivity 100% 99.68% 99.04% 98.09% 94.59% 90.13% 81.85% 66.88% 36.94% 13.38% 3.18% 0%
Specificity 0.30% 0.60% 1.81% 5.74% 15.41% 32.33% 50.76% 70.69% 91.84% 98.49% 99.09% 100%
PPV 48.76% 48.75% 48.90% 49.68% 51.47% 55.82% 61.19% 68.40% 81.12% 89.36% 76.92% -- -
NPV 51.24% 51.25% 51.10% 50.32% 48.53% 44.18% 38.81% 31.60% 18.88% 10.64% 23.08% -- -
a Sum of the minimum number of highly sensitive or highly specific signs/symptoms present for a suspect monkeypox case that also had ‘fever before rash’
https://doi.org/10.1371/journal.pntd.0005857.t006
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lymphadenopathy, fatigue, lesions of the same size, deep-seated firm lesions, lesions present
on the arms, legs, palms of the hands, or soles of the feet) on a MPX-specific case investigation,
followed by the classification of a patient as a suspect MPX case if they possessed a combina-
tion of any 7 or 8 of these specific signs/symptoms plus ‘fever before rash’. Suspected MPX
patients are rarely followed over the course of their infection. Patients are often only seen
once, the data on clinical signs/symptoms is assessed and captured at that single time point,
and no further follow-up is conducted. A definition such as the one suggested by the ROC
analysis may allow for greater flexibility and utility in detecting true MPX cases at any given
point during the course of the infection, since it allows for the presence of 7 or 8 signs/symp-
toms (versus 12). Additional evaluations to discern a specific suite of signs/symptoms that can
be easily identified by healthcare personnel in endemic areas are warranted. This could be fol-
lowed by modification of the surveillance investigation tool to incorporate the 12 signs/symp-
toms and evaluation of the utility of a new, modified case definition that accounts for the
presence of 7 or 8 signs/symptoms when determining if a patient is a suspected MPX case.
The population used in this analysis was a population of suspect MPX cases identified
through surveillance for human MPX illness in DRC. A total of 137 cases were excluded from
the final analysis due to incomplete data from case report forms (missing signs/symptoms).
Fig 2. A receiver operating characteristic analysis showing the area under the curve for the model
using the symptom ‘fever before rash’ and various summed frequencies of 12 signs/symptoms.
https://doi.org/10.1371/journal.pntd.0005857.g002
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The majority of excluded cases were laboratory-confirmed VZV cases (78 or 72.9% of those
excluded), which may lead to a slight bias in the dataset that contains relatively more labora-
tory-confirmed MPX cases than were identified in the surveillance dataset. However, a similar
proportion of laboratory-confirmed MPX and VZV cases were used for the analyses. Further,
data from the suspect MPX cases was collected at one point in time during their illness. The
dataset is unique in that it captured many signs/symptoms present for patient; similar datasets
with a large number of patients/cases are not available for independent comparison. This data
does not represent the spectrum of signs/symptoms that a patient may experience over the
course of their illness, and, the result may be a limitation in the frequency of signs/symptoms
for suspect cases. Nevertheless, this data reflected the range of presentations of signs/symptoms
recognized in suspected MPX patients in an area with endemic disease.
In order to document and detect endemic human MPX cases, a surveillance case definition
with more specificity in accurate case detection is needed. In rural DRC there are increasingly
limited resources, competing health priorities, and a lack of regional testing capacity, which
emphasizes the need to easily and efficiently deploy a case definition to accurately identify true
MPX patients and limit false positives. A single MPX case or the decision to launch an out-
break response requires considerable resources. According to national guidelines, once a MPX
case is identified, the case should be isolated and contacts should be followed for 21 days. Strict
recommendations regarding hygiene and infection control are instituted for the entire period
of illness, which can last for four weeks. In the absence of a more specific case definition, con-
tinued emphasis on laboratory-based diagnostics is warranted. More rapid and efficient meth-
ods of diagnosing suspect MPX patients, via a regional surveillance laboratory or a clinical
laboratory, are needed to better identify and care for patients followed by appropriate control
measures.
Disclaimer: The findings and conclusions in this report are those of the author(s) and do
not necessarily represent the views of the Centers for Disease Control and Prevention.
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